- Studio Aegle
- Posts
- Psilocibina
È difficile parlare di psichedelia oggi senza incrociare la psilocibina.
Estratta da funghi usati da secoli in contesti rituali, è diventata la protagonista indiscussa della ricerca contemporanea: depressione resistente, disturbi alimentari, ansia, dipendenze… ovunque si guardi, spunta uno studio nuovo.
In questa pagina trovi tutte le newsletter di Studio Aegle che parlano di psilocibina: trial clinici, riflessioni neuroscientifiche, dubbi metodologici, prospettive terapeutiche.
Depressione
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Raison, Charles L et al. “Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.” JAMA vol. 330,9 (2023): 843-853. doi:10.1001/jama.2023.14530
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin, Guy M et al. “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.” The New England journal of medicine vol. 387,18 (2022): 1637-1648. doi:10.1056/NEJMoa2206443
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Goodwin, Guy M et al. “Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol. 48,10 (2023): 1492-1499. doi:10.1038/s41386-023-01648-7
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
Rosenblat, Joshua D et al. “Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.” Med (New York, N.Y.) vol. 5,3 (2024): 190-200.e5. doi:10.1016/j.medj.2024.01.005
The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
Marwood, Lindsey et al. “The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.” Journal of psychiatric research vol. 180 (2024): 198-203. doi:10.1016/j.jpsychires.2024.10.009
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.
Back, Anthony L et al. “Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.” JAMA network open vol. 7,12 e2449026. 2 Dec. 2024, doi:10.1001/jamanetworkopen.2024.49026
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.
Lewis, Benjamin R et al. “Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.” medRxiv : the preprint server for health sciences 2024.12.31.24319806. 1 Jan. 2025, doi:10.1101/2024.12.31.24319806. Preprint.
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.
Kirlić, Namik et al. “Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.” The American journal of psychiatry vol. 182,1 (2025): 126-132. doi:10.1176/appi.ajp.20230884
Anoressia nervosa
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Peck, Stephanie Knatz et al. “Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.” Nature medicine vol. 29,8 (2023): 1947-1953. doi:10.1038/s41591-023-02455-9
Disturbo da dismorfismo corporeo
Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.
Xi Zhu et al. Genomic Press 2024 https://doi.org/10.61373/pp024r.0028
Bipolarismo
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
Aaronson, Scott T et al. “Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.” JAMA psychiatry vol. 81,6 (2024): 555-562. doi:10.1001/jamapsychiatry.2023.4685
Altro
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.
Mason, N L et al. “Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.” Brain, behavior, and immunity vol. 114 (2023): 299-310. doi:10.1016/j.bbi.2023.09.004
Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.
Rieser, Nathalie M et al. “Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.” Scientific reports vol. 13,1 17475. 14 Oct. 2023, doi:10.1038/s41598-023-44153-z
Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.
Singer, Berit et al. “Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.” Scientific reports vol. 14,1 7211. 26 Mar. 2024, doi:10.1038/s41598-024-55726-x
Psilocybin desynchronizes the human brain.
Siegel, Joshua S et al. “Psilocybin desynchronizes the human brain.” Nature vol. 632,8023 (2024): 131-138. doi:10.1038/s41586-024-07624-5
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.
Irrmischer, Mona et al. “Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.” Psychopharmacology vol. 242,4 (2025): 725-740. doi:10.1007/s00213-024-06733-3
Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.
Shahar, O., Botvinnik, A., Shwartz, A. et al. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Mol Psychiatry 29, 2059–2073 (2024). https://doi.org/10.1038/s41380-024-02477-w
The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation.
Gojani EG, Wang B, Li D-P, Kovalchuk O, Kovalchuk I. The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation. Genes. 2024; 15(2):183. https://doi.org/10.3390/genes15020183
Low nonpsychedelic doses of psilocybin for the therapy of MASLD.
EASL Congress 2024. Poster M. Colognesi et al.
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.
Nicholas, C.R., Banks, M.I., Lennertz, R.C. et al. Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry 14, 372 (2024). https://doi.org/10.1038/s41398-024-03059-8
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
de la Salle, S., Kettner, H., Thibault Lévesque, J. et al. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Sci Rep 14, 16524 (2024). https://doi.org/10.1038/s41598-024-66817-0
Non sei ancora iscrittə alla newsletter?